Dr. Philibert graduated from the University of Iowa Carver College of Medicine in 1989. He works in Iowa City, IA and specializes in Psychiatry. Dr. Philibert is affiliated with University Of Iowa Hospitals & Clinics.
Robert A. Philibert - Iowa City IA Edward I. Ginns - Bethesda MD Lynn Delisi - Stony Brook NY
Assignee:
The University of Iowa, as represented by the University of Iowa Research Foundation - Iowa City IA The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C07H 2104
US Classification:
435 6, 435 912, 536 231, 536 243, 536 2433
Abstract:
Nucleic acid sequences within the q13 region of the X chromosome having polymorphisms associated with neuropsychiatric disorders and associated conditions are disclosed herein. One polymorphism occurs within the coding region of the HOPA gene and introduces a four amino acid insertion into a putative OPA domain, a domain which has been shown to be involved in tissue specific expression. Compositions including nucleic acids having these polymorphisms and antibodies to polymorphic regions within proteins encoded in the PCTG4 region are provided. Methods of using the information and nucleic acid sequences disclosed herein for the diagnosis and assessment of pathologies associated with neuropsychiatric disorders and associated conditions are also provided.
Compositions And Methods For Detecting Predisposition To A Substance Use Disorder
Robert Philibert - Iowa City IA, US Anup Madan - Bellevue WA, US
International Classification:
C07H 21/02 G01N 33/44
US Classification:
536 231, 436 94
Abstract:
The present invention provides screening kits, compositions, and diagnostic methods for determining whether a subject has a predisposition to, or likelihood of having, a substance use disorder by determining a nucleic acid methylation profile from a biological sample from the subject, wherein a given profile indicates that the subject has a predisposition to a substance use disorder.
Regulation Of The Serotonin Reuptake Transporter And Disease
Described herein is a CpG island in the 5′ region of the 5HTT gene that contains an alternative exon 1 and promoter for 5HTT. Methylation at this CpG island is associated with decreased levels of 5HTT mRNA, and this effect is evident when 5HTTLPR genotype is taken into account. Thus, this methylation status indicates 5HTT mRNA production, which serves as an indicator for the expression of the transporter and of a subject's vulnerability to diseases related to serotonergic activity. Accordingly, certain embodiments of the present invention provide diagnostic methods for determining whether a subject has, or is at risk for developing, a disease associated with serotonergic activity.
Compositions And Methods For Detecting Predisposition To A Substance Use Disorder Or To A Mental Illness Or Syndrome
Robert Philibert - University Heights IA, US Anup Madan - Bellevue WA, US
International Classification:
C12Q 1/68 G01N 33/00
US Classification:
435006000, 436094000
Abstract:
The present invention provides screening kits, compositions, and diagnostic methods for determining whether a subject has a predisposition to, or likelihood of having, a substance use disorder or mental illness or syndrome by determining a nucleic acid expression profile from a biological sample from the subject, wherein a given profile indicates that the subject has a predisposition to a substance use disorder or mental illness or syndrome.
Regulation Of The Serotonin Reuptake Transporter And Disease
Robert Philibert - Iowa City IA, US Anup Madan - Iowa City IA, US
Assignee:
University of Iowa Research Foundation - Iowa City IA
International Classification:
C12Q 1/68
US Classification:
435 611
Abstract:
Described herein is a CpG island in the 5′ region of the 5HTT gene that contains an alternative exon 1 and promoter for 5HTT. Methylation at this CpG island is associated with decreased levels of 5HTT mRNA, and this effect is evident when 5HTTLPR genotype is taken into account. Thus, this methylation status indicates 5HTT mRNA production, which serves as an indicator for the expression of the transporter and of a subject's vulnerability to diseases related to serotonergic activity. Accordingly, certain embodiments of the present invention provide diagnostic methods for determining whether a subject has, or is at risk for developing, a disease associated with serotonergic activity.
Compositions And Methods For Correcting For Cellular Admixture In Epigenetic Analyses
- Coralville IA, US Robert Philibert - Iowa City IA, US
International Classification:
C12Q 1/6858 C12Q 1/6881
Abstract:
This disclosure relates to differentially methylated regions (DMRs) and an equation that can be applied when using epigenetic analysis in a biological sample that includes more than one cell type and, therefore, more than one methylation set point (e.g., saliva). This disclosure relates to differentially methylated regions (DMRs) and an equation that can be applied when using epigenetic analysis in a biological sample that includes more than one cell type and, therefore, more than one methylation set point (e.g., saliva).
This disclosure describes the use of a phosphodiesterase-5 (PDE5) inhibitor to reduce an individual's desire to smoke and/or frequency of smoking. In some embodiments, the PDE5 inhibitor is sildenafil (e.g., Viagra).
Compositions And Methods For Detecting Predisposition To Cardiovascular Disease